Sundfør K, Trope C G, Kjørstad K E
Department of Gynecologic Oncology, the Norwegian Radium Hospital, Oslo.
Acta Oncol. 1996;35 Suppl 8:99-107. doi: 10.3109/02841869609098527.
To investigate whether surgery or radiotherapy should be preferred in the early stages of carcinoma of the cervix a randomized study was performed in which operable patients with small FIGO stage 2 squamous cell carcinoma were included. Of these patients, 122 were in stage 2A and 20 in stage 2B. The patients were treated with intracavitary radium, followed by either radical surgery with pelvic lymphadenectomy (Group A, 72 patients) or high-voltage external irradiation 40 Gy to a pelvic field (Group B, 70 patients). Postoperative irradiation 40 to 50 Gy was given in Group A if lymph node metastases were found at operation. Fourteen patients in Group A and 23 in Group B died of recurrent disease. The 5-, 10-, and 20-year survival in Group A was 87, 84 and 81% respectively compared with 72, 69, and 68% in Group B, p < 0.05. Twenty-three (34%) of 67 radically operated patients had metastases to pelvic lymph nodes. A high rate of pelvic and para-aortic recurrences accounts for the difference between Groups A and B. Young patients (<40 years) with large tumours had a high risk of recurrent disease. Severe urinary and gastrointestinal complications were more common in Group A, especially among patients given postoperative radiotherapy. Lymphoedema was seen almost exclusively in Group A. Two patients in Group A and one in Group B died of complications to treatment. The corrected 10-year survival of 69.5% as achieved in the radiotherapy arm of this series is comparable to other reported studies. The high survival rate in the operated group, despite a very high metastases rate, suggests that surgery is applicable also in stage 2 patients.
为了研究在宫颈癌早期阶段手术和放疗哪种更具优势,进行了一项随机研究,纳入了FIGO 2期小鳞状细胞癌的可手术患者。在这些患者中,122例为2A期,20例为2B期。患者接受腔内镭疗,随后分别接受根治性手术加盆腔淋巴结清扫术(A组,72例患者)或盆腔野40 Gy的高能外照射(B组,70例患者)。如果A组患者在手术中发现淋巴结转移,则术后给予40至50 Gy的放疗。A组有14例患者、B组有23例患者死于复发性疾病。A组的5年、10年和20年生存率分别为87%、84%和81%,而B组分别为72%、69%和68%,p<0.05。67例接受根治性手术的患者中有23例(34%)出现盆腔淋巴结转移。盆腔和腹主动脉旁复发率高是A组和B组之间存在差异的原因。年轻(<40岁)且肿瘤较大的患者复发疾病风险较高。严重的泌尿系统和胃肠道并发症在A组更常见,尤其是接受术后放疗的患者。淋巴水肿几乎仅见于A组。A组有2例患者、B组有1例患者死于治疗并发症。本系列放疗组所达到的经校正的10年生存率为69.5%,与其他报道的研究结果相当。尽管转移率非常高,但手术组的高生存率表明手术也适用于2期患者。